Investigational drug · Phase 2
KAND567
Also called: Fractalkine
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 8, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "KAND567"
First trial start
2023
Apr 26, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KAND567", any sponsor or status.
Conditions studied
As listed on its trial records.
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "KAND567" as an intervention, largest first.
Novakand Pharma ABIndustry
NCT06012565 · 35 participants · Start Oct 11, 2020 · Primary completion Aug 7, 2021
Drug: KAND567; Microcrystalline cellulose · For: Covid19
Sites: Hvidovre, Denmark; Odense, Denmark; Stockholm, Sweden · 4 sites in all
Novakand Pharma ABIndustry
NCT06030375 · 23 participants · Start Feb 17, 2020 · Primary completion Apr 27, 2020
Drug: KAND567 · For: Healthy
Sites: Turku, Finland
Novakand Pharma ABIndustry
NCT06087289 · 18 participants · Start Apr 26, 2023 · Primary completion Apr 3, 2025
Drug: KAND567; Carboplatin · For: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Sites: Odense, Denmark; Oslo, Norway; Lund, Sweden · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Effect of Fractalkine Signaling on Neuroinflammation and Neuropathic Pain-like Behavior in Mice.
Fan Q, Kim J, Zhang J, et al. · Anesthesiology 2026
- Inflammatory biomarkers of obstructive sleep apnea: a comprehensive review from known to novel.
Esmaeeli S · Mol Biol Rep 2026
- Does high fructose consumption trigger microglia activation and neuroinflammation? A systematic review.
Olasehinde TA, Hernadez-Ledesma B, Gómez-Cortés P, et al. · Food Chem Toxicol 2026
- Chemopreventive Effect of Bitter Melon (Momordica charantia) Juice on Pancreatic Carcinogenesis in LSL-KrasG12D /+; p48Cre/+ Mice.
Bugata LSP, Dhar D, Kant R, et al. · Mol Carcinog 2026
- Mechanism of Shanhu Qishiwei pills in regulating endoplasmic reticulum stress through GRP78/CHOP signaling pathway for the treatment of cerebral ischemia.
Yang Y, Di Q, Cheng Y, et al. · J Ethnopharmacol 2026
- Fractalkine produced by Shiga toxin type 2-stimulated human glomerular endothelial cells modulates γδ T lymphocyte migration.
Rosso DA, Rosato M, Ledesma M, et al. · Front Immunol 2026
Also in development for Epithelial Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- AZD5335Torvutatug samrotecan, Torvu-samPhase 34 trials
AstraZeneca · Epithelial Ovarian Cancer, Ovarian Cancer, Lung Adenocarcinoma
- IMNN-001IL-12 Plasmid with PEG-PEI-Cholesterol Lipopolymer, GEN-1Phase 33 trials
Imunon · Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer
- RC88The RC88Phase 23 trials
RemeGen Co., Ltd. · Solid Tumor, Advanced Solid Tumours, Primary Peritoneal Cancer
- AVZO-021Phase 22 trials
Avenzo Therapeutics, Inc. · HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Advanced Solid Tumor
- Dual-target CAR-NK cell productPhase 22 trials
Beijing Biotech · Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma
- CBX-12Phase 21 trial
Cybrexa Therapeutics · Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma
- ETX-19477Phase 21 trial
858 Therapeutics, Inc. · Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.